Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.
about
Assessment of tracer 99mTc(V)-DMSA uptake as a measure of tumor cell proliferation in vitro.Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.Targeted therapy in rare cancers--adopting the orphans.Canonical and new generation anticancer drugs also target energy metabolism.Conformational landscape and low lying excited states of imatinib.CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT.
P2860
Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Imatinib mesylate: past succes ...... strointestinal stromal tumors.
@ast
Imatinib mesylate: past succes ...... strointestinal stromal tumors.
@en
type
label
Imatinib mesylate: past succes ...... strointestinal stromal tumors.
@ast
Imatinib mesylate: past succes ...... strointestinal stromal tumors.
@en
prefLabel
Imatinib mesylate: past succes ...... strointestinal stromal tumors.
@ast
Imatinib mesylate: past succes ...... strointestinal stromal tumors.
@en
P2860
P356
P1476
Imatinib mesylate: past succes ...... strointestinal stromal tumors.
@en
P2093
Doran Ksienski
P2860
P304
P356
10.4137/CMO.S4259
P407
P577
2011-11-09T00:00:00Z